SF1670|cas:345630-40-2|西域试剂

SF1670,98.0%

产品编号：Bellancom-15842| CAS NO：345630-40-2| 分子式：C₁₉H₁₇NO₃| 分子量：307.34

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-15842	￥1000.00	杭州北京（现货）
Bellancom-15842	￥1500.00	杭州北京（现货）
Bellancom-15842	￥3300.00	杭州北京（现货）
Bellancom-15842	￥5300.00	杭州北京（现货）
Bellancom-15842	￥7600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SF1670

产品介绍

SF1670 是一种有效的特异性的人第10号染色体缺失的磷酸酶及张力蛋白同源蛋白 (PTEN) 抑制剂。

生物活性

SF1670 is a potent and specific phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor.

体外研究

SF1670 is a specific PTEN inhibitor with prolonged intracellular retention in neutrophils. SF1670 enhances PtdIns(3,4,5)P3 signaling in transplanted neutrophils. SF1670 also elevates Akt phosphorylation in murine cells. Consistent with the enhanced Akt phosphorylation, pretreatment with SF1670 also significantly augments PtdIns(3,4,5)P3 level in mouse neutrophils. SF1670-induced Akt hyperactivation is abolished in PTEN-null neutrophils, further demonstrating that this effect is mediated by specific inhibition of PTEN activity. At 500 nM fMLP stimulation, SF1670 (500 nM)–pretreated neutrophils show nearly 70% higher (maximal) superoxide production than untreated neutrophils. HCT116 cells are pre-treated with the PTEN inhibitor SF1670 (2 μM) for 24 h (untreated HCT116 cells served as control); treated cells are subsequently plated under non-adherent conditions with added MET (60 μM), Lun (2 μM), or Gen (2 μM). SF1670 binds to the PTEN active site, resulting in elevated phosphatidylinositol (3,4,5) triphosphate signaling.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

SF1670 (3 mg/kg; i.p.) triggers postconditioning after inducing cerebral global ischaemia (17 min) and reperfusion (24 h)‐induced injury via occlusion of both carotid arteries in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Swiss albino male mice (bodyweight 25-30 g)
Dosage:	3 mg/kg
Administration:	Treatment with i.p.
Result:	Lead to attenuation of cerebral I/R-induced increase in thiobarbituric acid reactive substances (TBARS).

体内研究

SF1670 (3 mg/kg; i.p.) triggers postconditioning after inducing cerebral global ischaemia (17 min) and reperfusion (24 h)‐induced injury via occlusion of both carotid arteries in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Swiss albino male mice (bodyweight 25-30 g)
Dosage:	3 mg/kg
Administration:	Treatment with i.p.
Result:	Lead to attenuation of cerebral I/R-induced increase in thiobarbituric acid reactive substances (TBARS).

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 50 mg/mL (162.69 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.2537 mL	16.2686 mL	32.5373 mL
5 mM	0.6507 mL	3.2537 mL	6.5075 mL
10 mM	0.3254 mL	1.6269 mL	3.2537 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.13 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.13 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。